Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology
Disease Category: Depression (Major/Severe)
Trial Information
A three-phase study designed to test the efficacy, tolerability and safety of the
combination of Ziprasidone with the selective serotonin reuptake inhibitor (SSRI)
Escitalopram for patients with Major Depressive Disorder (MDD) that do not sufficiently
respond to treatment with Escitalopram
The current research study is looking for participants between the ages of 18-65, who are depressed and are not currently taking any medication. If eligible, participants will receive the FDA approved antidepressant medication Escitalopram (Lexapro) for at least 10 weeks. At the end of 10 weeks, subjects who have improved on the medication will be offered 3 months of follow up care at no cost. For those subjects who have NOT improved on the medication, they may be eligible to continue on Lexapro and receive, in addition, either Ziprasidone or placebo. Placebo is sometimes called a sugar pill, and it looks like a study drug but it doesn’t contain any active medication. At the end of the study, all participants will be offered 3 months of follow up care at no cost.
For more information about this and other depression studies, please call 1-877-55-BLUES or contact Vicki directly at 617-724-9458 or vameral@partners.org
Victoria Ameral, CRC
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Phone: 617-724-9458
EMail: vameral@partners.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
